Patents by Inventor Yichen Lu
Yichen Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230172513Abstract: Flexible, insertable, transparent microelectrode arrays that allow integration of electrophysiological recordings with any optical imaging or stimulation technology are disclosed. In some embodiments of the disclosed technology, a microelectrode array includes a flexible substrate layer including a shank member extending in a first direction and a tapered tip at an end of the shank member, and a plurality of electrode wires arranged in the first direction on the flexible substrate layer, wherein the plurality of electrode wires includes adjacent electrode wires having different lengths from each other such that an electrode wire arranged closer to a centerline of the flexible substrate layer is longer than an adjacent electrode arranged further away from the centerline of the flexible substrate.Type: ApplicationFiled: December 7, 2022Publication date: June 8, 2023Inventors: Duygu Kuzum, Yichen Lu, Xin Liu, Jeong-hoon Kim
-
Patent number: 9968666Abstract: The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: GrantFiled: June 11, 2010Date of Patent: May 15, 2018Assignee: Vaccine Technologies, IncorporatedInventors: Yichen Lu, Nicholas Kushner, Amie Strong, Zhenghui Xu
-
Patent number: 9244061Abstract: Described are compositions and methods for detecting or monitoring the ability of an individual to mount a cell mediated immune response to a target antigen. Methods rely in part upon the physical association, e.g., by fusion, of a Lethal Factor (LF) polypeptide with a target antigen. The LF polypeptide moiety, including, for example, an LFn polypeptide moiety, serves as a transport factor to deliver target antigens, including full length target polypeptides, to the cytosol of an intact, living immune cell from an individual. Measurement of a cytokine response by the immune cell from the individual provides a read out of a cell mediated immune response. The methods and compositions described provide diagnostic as well as prognostic information and can guide the direction of therapy.Type: GrantFiled: June 11, 2010Date of Patent: January 26, 2016Assignee: Vaccine Technologies, IncorporatedInventors: Yichen Lu, Neal Touzjian, Huishan Guo, Wenbiao Zheng
-
Publication number: 20130115237Abstract: The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a Bacillus anthracis lethal factor (LF) polypeptide, such as a LFn polypeptide. In some embodiments, the LF polypeptide can be fused or otherwise associated with the HIV polypeptide. Other aspect of the present invention relate to use of vaccine comprising a HIV polypeptide and a Bacillus anthracis lethal factor (LF) polypeptide in methods to enhance efficacy traditional antiretroviral therapy.Type: ApplicationFiled: June 9, 2011Publication date: May 9, 2013Applicant: VACCINE TECHNOLOGIES, INCORPORATEDInventors: Yichen Lu, Huyen Cao
-
Patent number: 8333953Abstract: The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: GrantFiled: May 18, 2010Date of Patent: December 18, 2012Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: Yichen Lu, Huyen Cao
-
Publication number: 20120172254Abstract: Described are compositions and methods for detecting or monitoring the ability of an individual to mount a cell mediated immune response to a target antigen. Methods rely in part upon the physical association, e.g., by fusion, of a Lethal Factor (LF) polypeptide with a target antigen. The LF polypeptide moiety, including, for example, an LFn polypeptide moiety, serves as a transport factor to deliver target antigens, including full length target polypeptides, to the cytosol of an intact, living immune cell from an individual. Measurement of a cytokine response by the immune cell from the individual provides a read out of a cell cell from mediated immune response. The methods and compositions described provide diagnostic as well as prognostic information and can guide the direction of therapy.Type: ApplicationFiled: June 11, 2010Publication date: July 5, 2012Applicant: Vaccine Technologies, IncorporatedInventors: Yichen Lu, Neal Touzjian, Huishan Guo, Wenbiao Zheng
-
Publication number: 20120148621Abstract: The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: ApplicationFiled: June 11, 2010Publication date: June 14, 2012Applicant: VACCINE TECHNOLOGIES, INCORPORATEDInventors: Yichen Lu, Nicholas Kuchner, Amie Strong, Zhenhui Xu
-
Publication number: 20100311105Abstract: The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: ApplicationFiled: May 18, 2010Publication date: December 9, 2010Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATIONInventors: Yichen Lu, Huyen Cao
-
Patent number: 7754219Abstract: The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: GrantFiled: March 28, 2002Date of Patent: July 13, 2010Assignees: President and Fellows of Harvard College, The General Hospital CorporationInventors: Yichen Lu, Huyen Cao
-
Publication number: 20050220807Abstract: The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.Type: ApplicationFiled: March 28, 2002Publication date: October 6, 2005Inventors: Yichen Lu, Huyen Cao
-
Patent number: 5891444Abstract: A composition and method for inducing a protective immune response to HIV-1 in an individual, of (a) a replication incompetent HIV-1, HIV-1 pseudovirus, HIV-1 VLP or oligomeric gp120; and (b) a water soluble polyphosphazene polyelectrolyte, wherein (a) and (b) are present in an amount effective to induce a protective immune response against HIV-1.Type: GrantFiled: June 7, 1995Date of Patent: April 6, 1999Assignee: Virus Research Institute, Inc.Inventors: Sharon Jenkins, Yichen Lu, Lendon Payne, Bryan Roberts
-
Patent number: 5733760Abstract: A modified Salmonella, wherein the wild type pag gene such as pagC has been replaced by a gene encoding a truncated pag gene such as pagC gene fused to a heterologous DNA segment, is disclosed. This modification significantly attenuates the virulence of the Salmonella. In addition, immune reaction to the portion of the fusion protein encoded by the heterologous gene can be generated. Uses of the vector, including its use in a drug screen are also disclosed.Type: GrantFiled: August 5, 1994Date of Patent: March 31, 1998Assignees: Virus Research Institute, The General Hospital CorporationInventors: Yichen Lu, Samuel I. Miller, Kevin Killeen